265 related articles for article (PubMed ID: 6282375)
21. Effects of RP and SP diastereoisomers of adenosine 5'-O-(1-thiodiphosphate) on human platelets.
Cusack NJ; Hourani SM
Br J Pharmacol; 1981 Jun; 73(2):409-12. PubMed ID: 7236993
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin.
Farndale RW; Winkler AB; Martin BR; Barnes MJ
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):25-32. PubMed ID: 1311555
[TBL] [Abstract][Full Text] [Related]
23. Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.
Hourani SM; Hall DA; Nieman CJ
Br J Pharmacol; 1992 Feb; 105(2):453-7. PubMed ID: 1559134
[TBL] [Abstract][Full Text] [Related]
24. Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1-receptors.
Vanderwel M; Lum DS; Haslam RJ
FEBS Lett; 1983 Dec; 164(2):340-4. PubMed ID: 6317457
[TBL] [Abstract][Full Text] [Related]
25. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of ADP receptors.
Cusack NJ; Hourani SM; Welford LA
Adv Exp Med Biol; 1985; 192():29-39. PubMed ID: 3010670
[No Abstract] [Full Text] [Related]
27. ADP-induced platelet aggregation and inhibition of adenylyl cyclase activity stimulated by prostaglandins: signal transduction mechanisms.
Puri RN
Biochem Pharmacol; 1999 Apr; 57(8):851-9. PubMed ID: 10086317
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of adenylate cyclase activity during the reversible shape change in human platelets.
Dimitrov DP; Bühler FR
Biochem Biophys Res Commun; 1988 Apr; 152(2):649-57. PubMed ID: 3365246
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
Kahn NN; Sinha AK
Biochim Biophys Acta; 1989 Aug; 984(1):113-8. PubMed ID: 2548620
[TBL] [Abstract][Full Text] [Related]
30. 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation.
Cusack NJ; Hourani SM
Br J Pharmacol; 1981 Mar; 72(3):443-7. PubMed ID: 7260485
[TBL] [Abstract][Full Text] [Related]
31. Partial agonist behaviour of adenosine 5'-O-(2-thiodiphosphate) on human platelets.
Cusack NJ; Hourani SM
Br J Pharmacol; 1981 Jun; 73(2):405-8. PubMed ID: 7236992
[TBL] [Abstract][Full Text] [Related]
32. Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway.
Jakobs KH; Bauer S; Watanabe Y
Eur J Biochem; 1985 Sep; 151(2):425-30. PubMed ID: 4040856
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.
Park HS; Hourani SM
Br J Pharmacol; 1999 Jul; 127(6):1359-66. PubMed ID: 10455285
[TBL] [Abstract][Full Text] [Related]
34. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
[TBL] [Abstract][Full Text] [Related]
35. Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
Motulsky HJ; Shattil SJ; Ferry N; Rozansky D; Insel PA
Mol Pharmacol; 1986 Jan; 29(1):1-6. PubMed ID: 2418346
[TBL] [Abstract][Full Text] [Related]
36. Platelet alpha-2 adrenoceptor-mediated primary aggregation and adenylate cyclase inhibition in depressed patients.
Karege F; Bovier P; Hilleret H; Gaillard JM
Lancet; 1993 Apr; 341(8851):1029. PubMed ID: 8096917
[No Abstract] [Full Text] [Related]
37. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
Seiler S; Brassard CL; Federici ME
Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
[TBL] [Abstract][Full Text] [Related]
38. Proteolysis of the platelet surface: dissociation of shape change from aggregation.
Kornecki E; Ehrlich YH; Hardwick DH; Lenox RH
Am J Physiol; 1986 Apr; 250(4 Pt 2):H550-7. PubMed ID: 3008579
[TBL] [Abstract][Full Text] [Related]
39. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
40. Forskolin sensitizes human platelet adenylate cyclase to modulation of substrate (MgATP) affinity by hormones.
Watanabe Y; Jakobs KH
Biochem J; 1986 Jul; 237(1):273-6. PubMed ID: 3492195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
